Spinal muscular atrophy

SMA-MLPA (SMN1 & SMN2)

Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord (α-motor neurons) this leads to symmetrical muscle weakness and atrophy. α-motor neurons are located in the anterior grey matter of the spinal cord that are concentrated in the cervical and lumbosacral enlargements. SMA is an autosomal recessive (AR) disease. In about 95% of SMA patients, involvement of homozygous deletion of the survival motor neuron 1 (SMN1) gene or its conversion to the highly homologous SMN2 gene is observed. SMN2 gene copy number correlates to disease severity. MLPA-based assay is an efficient & accurate method to detect SMN1 and SMN2 copy numbers with high specificity and low complexity

Severity and types of SMA

The severity of SMA and the age of onset can vary depending on the specific genetic mutation. SMA is divided into four types based on the age of onset and the severity of symptoms:

  • SMA Type 1 (Werdnig-Hoffmann disease): This is the most severe form of SMA, typically appearing in infancy. Infants with SMA Type 1 have significant muscle weakness, poor muscle tone (hypotonia), and difficulty with swallowing and breathing. They may have difficulty sitting or achieving motor milestones.
  • SMA Type 2: This form of SMA usually becomes apparent in early childhood. Children with SMA Type 2 can generally sit unsupported but may have difficulty standing or walking independently. They may experience progressive muscle weakness and respiratory problems.
  • SMA Type 3 (Kugelberg-Welander disease): This form of SMA typically starts in childhood or adolescence. Individuals with SMA Type 3 can often walk independently, but they may develop muscle weakness and experience difficulty with climbing stairs or walking long distances.
  • SMA Type 4: This is the mildest form of SMA, with symptoms typically appearing in adulthood. People with SMA Type 4 may experience mild muscle weakness and have a normal lifespan.

References

  1. Ogino, S. & Wilson, R. B. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Human Genetics (2002). doi:10.1007/s00439-002-0828-x
  2. Arnold, W. D., Kassar, D. & Kissel, J. T. Spinal muscular atrophy: Diagnosis and management in a new therapeutic era. Muscle and Nerve (2015). doi:10.1002/mus.24497
  3. Nilay M, Moirangthem A, Saxena D, et al. Carrier frequency of SMN1- related spinal muscular atrophy in north Indian population: The need for population based screening program. Am J Med Genet A. 2020 October 14. doi: 10.1002/ajmg.a.61918. Epub ahead of print. PMID: 33051992.

Sample Requirements

  • Blood (3-5 ml)
  • DNA (1-5 ug, 260/280 ratio=1.8-2.0)

The General Workflow For Whole Genome Sequencing include;

  • DNA isolation and Quality Check
  • Library Preparation
  • Sequencing
  • Bioinformatics analysis
  • Reporting

Methodology

  • MLPA

TAT

  • 2 Weeks

Need a free Consultation?

JUST MAKE AN APPOINTMENT & YOU'RE DONE!

-Progenics-

Free Genetic Counseling by Progenics Genetic Experts